Alberto Herreros de Tejada

Dr. Alberto Herreros de Tejada

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2019 in Gastroenterology
Verified
Journal Article
Closed access
EAEduardo Albéniz
Eduardo Albéniz
MÁMarco Antonio Álvarez-González
Marco Antonio Álvarez-González
JEJorge C. Espinós
Jorge C. Espinós
ONOscar Nogales
Oscar Nogales
CGCarlos Guarner
Carlos Guarner
MEMónica Enguita-Germán
Mónica Enguita-Germán

1 July 2017 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
CECecilia M. Egoavil
Cecilia M. Egoavil
MJMiriam Juárez
Miriam Juárez
CGCarla Guarinos
Carla Guarinos
MRMaría Rodríguez-Soler
María Rodríguez-Soler
EHEva Hernández-Illán
Eva Hernández-Illán
Rodrigo JoverRodrigo Jover
Rodrigo Jover

30 July 2025 in Gastroenterology
Verified
Journal Article
Closed access
DRDiego de Frutos Rosa
Diego de Frutos Rosa
ISIsabel Alonso Sebastián
Isabel Alonso Sebastián
DDDavid Barquero Declara
David Barquero Declara
JCJesús Badia Closa
Jesús Badia Closa
ÓNÓscar Nogales
Óscar Nogales
ATAlberto Herreros de Tejada
Alberto Herreros de Tejada

31 December 2025 in Endoscopy
Verified
Journal Article
Closed access
PDF file
ESEnrique Rodríguez de Santiago
Enrique Rodríguez de Santiago
CSCarlos Teruel Sánchez-Vegazo
Carlos Teruel Sánchez-Vegazo
EAEduardo Albéniz
Eduardo Albéniz
FAFermín Estremera Arévalo
Fermín Estremera Arévalo
AGAmaia Arrubla Gamboa
Amaia Arrubla Gamboa
AAAgustín Albillos
Agustín Albillos
Background Antireflux mucosal ablation (ARMA) is a novel endoscopic technique for gastroesophageal reflux disease (GERD) but has only been assessed in noncontrolled studies. The objective of this randomized controlled study was to evaluate its efficacy in patients with proton pump inhibitor (PPI)-responsive GERD. Methods We conducted a double-blind, sham endoscopy-controlled, randomized trial across 12 Spanish hospitals. Adults with PPI-responsive GERD and abnormal esophageal acid exposure time (AET > 6 %) were randomly assigned (1:1) to receive ARMA or sham endoscopy. The primary outcome was clinical success at 12 months, defined as a ≥ 50 % reduction in the GERD-Health-Related Quality of Life score. Inability to discontinue PPIs to allow symptom assessment was considered treatment failure. Secondary outcomes included PPI discontinuation, AET, manometric parameters, mucosal healing, and adverse events. Results Of 186 patients screened, 60 were included (ARMA 31; sham 29). At 12 months, clinical success was achieved in 16 patients (51.6 %) in the ARMA group and in 11 (37.9 %) in the sham group (P = 0.29; risk ratio 1.36, 95 %CI 0.76 to 2.42). No significant differences were observed in PPI discontinuation, AET, manometric findings, or mucosal healing. Postprocedural pain (27.3 % vs. 3.3 %) and dysphagia (45.5 % vs. 10.0 %) occurred more frequently in the ARMA group. No severe adverse events were recorded. Conclusions ARMA was not superior to sham endoscopy in improving GERD-related quality of life at 12 months in patients with PPI-responsive GERD, and was associated with a higher incidence of adverse events. These findings do not support its implementation in routine clinical practice.

24 October 2023 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
NGNatalia González-López
Natalia González-López
EQEnrique Quintero
Enrique Quintero
AGAntonio Z. Gimeno-Garcia
Antonio Z. Gimeno-Garcia
LBLuis Bujanda
Luis Bujanda
JBJesús Banales
Jesús Banales
OGOn behalf of the Oncology Group of Asociación Española de Gastroenterología
On behalf of the Oncology Group of Asociación Española de Gastroenterología
Background: Colonoscopy screening is underused by first-degree relatives (FDRs) of patients with non-syndromic colorectal cancer (CRC) with screening completion rates below 50%. Studies conducted in FDR referred for screening suggest that fecal immunochemical testing (FIT) was not inferior to colonoscopy in terms of diagnostic yield and tumor staging, but screening uptake of FIT has not yet been tested in this population. In this study, we investigated whether the uptake of FIT screening is superior to the uptake of colonoscopy screening in the familial-risk population, with an equivalent effect on CRC detection. Methods and findings: This open-label, parallel-group, randomized trial was conducted in 12 Spanish centers between February 2016 and December 2021. Eligible individuals included asymptomatic FDR of index cases <60 years, siblings or ≥2 FDR with CRC. The primary outcome was to compare screening uptake between colonoscopy and FIT. The secondary outcome was to determine the efficacy of each strategy to detect advanced colorectal neoplasia (adenoma or serrated polyps ≥10 mm, polyps with tubulovillous architecture, high-grade dysplasia, and/or CRC). Screening-naïve FDR were randomized (1:1) to one-time colonoscopy versus annual FIT during 3 consecutive years followed by a work-up colonoscopy in the case of a positive test. Randomization was performed before signing the informed consent using computer-generated allocation algorithm based on stratified block randomization. Multivariable regression analysis was performed by intention-to-screen. On December 31, 2019, when 81% of the estimated sample size was reached, the trial was terminated prematurely after an interim analysis for futility. Study outcomes were further analyzed through 2-year follow-up. The main limitation of this study was the impossibility of collecting information on eligible individuals who declined to participate. A total of 1,790 FDR of 460 index cases were evaluated for inclusion, of whom 870 were assigned to undergo one-time colonoscopy (n = 431) or FIT (n = 439). Of them, 383 (44.0%) attended the appointment and signed the informed consent: 147/431 (34.1%) FDR received colonoscopy-based screening and 158/439 (35.9%) underwent FIT-based screening (odds ratio [OR] 1.08; 95% confidence intervals [CI] [0.82, 1.44], p = 0.564). The detection rate of advanced colorectal neoplasia was significantly higher in the colonoscopy group than in the FIT group (OR 3.64, 95% CI [1.55, 8.53], p = 0.003). Study outcomes did not change throughout follow-up. Conclusions: In this study, compared to colonoscopy, FIT screening did not improve screening uptake by individuals at high risk of CRC, resulting in less detection of advanced colorectal neoplasia. Further studies are needed to assess how screening uptake could be improved in this high-risk group, including by inclusion in population-based screening programs. Trial registration: This trial was registered with ClinicalTrials.gov (NCT02567045).

20 November 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
KWKatarzyna Winter
Katarzyna Winter
PKPrzemysław Piotr Kasprzyk
Przemysław Piotr Kasprzyk
ZNZuzanna Nowicka
Zuzanna Nowicka
SNSuzuki Noriko
Suzuki Noriko
ATAlberto Herreros de Tejada
Alberto Herreros de Tejada
MSMichał Spychalski
Michał Spychalski
Background: Endoscopic submucosal dissection (ESD) is a reliable method that can replace surgery in the treatment of early colorectal cancer under certain conditions. Aim: The aim of the study was to analyze factors influencing the ESD procedure in early colorectal cancer, with the intention of improving its effectiveness. Patients and Methods: We conducted a multicenter, retrospective cohort study on 214 patients who underwent ESD procedures for early colorectal cancer from January 2016 to October 2023. Results:En bloc resection was achieved in 197 (92.1%) of ESD procedures, R0 resection in 149 (69.6%), and curative resection in 54 (40.9%). The submucosal invasion was classified as level 1 (SM1) in 96 cases (45.3%), level 2 (SM2) in 61 cases (28.8%), and level 3 (SM3) in 36 cases (17%). R0 resection was achieved more often in the rectum—92 (81.4%), compared to the right—24 (64.9%) and left colon—33 (61.1%), p = 0.009. In rectal tumors, R0 resection was achieved in 51 (98.1%) SM1 invasion, 27 (73%) SM2 invasion, and 13 (65%) SM3 invasion (p < 0.001). Lateral and vertical resection margins were positive in 12 (7.7%) and 52 (25.2%) cases, respectively. Vertical resection margins were statistically more often positive in lesions located in the right colon—11 cases (28.9%) and left colon—21 cases (38.9%), than in rectum—20 cases (17.5%); p = 0.010. Complications were found in 32 (15%) cases of ESD procedure—perforation in 12 cases (5.6%) and delayed bleeding in four cases (1.9%). Procedures performed in the right colon were associated with a significantly higher risk of any complications (30%) and perforations (15%) than those performed in the rectum (10.3% and 2.6%) or the left colon (13.8% and 5.2%; p = 0.016; p = 0.015), respectively. Conclusions: ESD for early colon cancer is a viable strategy due to its effectiveness and low complication rate. The ESD technique performed in the rectum yields the best results; however, in the right colon, it still requires careful attention.